同基因造血干细胞移植治疗再生障碍性贫血11例疗效分析

Syngeneic hematopoietic stem cell transplantation for aplastic anemia

目的评价同基因造血干细胞移植(syn-HSCT)治疗再生障碍性贫血(AA)的疗效。方法对11例接受syn-HSCT的AA患者进行回顾性分析。结果全部11例AA患者中男4例,女7例,中位年龄为22(7~44)岁。全部11例患者移植后均获得造血重建,中位粒细胞植入时间为10(8~23)d,中位血小板植入时间为11(8~28)d。8例患者获得长期稳定植入,3例患者植入失败,其中2例行二次移植(1例获得到长期稳定植入,另1例造血重建后再次发生植入失败)。中位随访时间为53(5~135)个月,全部11例患者均存活,其中9例患者外周血象长期正常。结论syn-HSCT治疗AA可获得良好的长期生存,植入失败仍是有待解决的主要问题。

Objective To evaluate the efficacy of syngeneic hematopoietic stem cell transplantation in the treatment of aplastic anemia.Methods The clinic data of 11 patients with aplastic anemia undergoing syngeneic HSCT were retrospectively analyzed.Results Among all of the 11 patients with AA,4 males and 7 females were determined,with a median age of 22(7-44)years old.All of the 11 patients achieved engraftment after the first transplantation:neutrophils engraftment occurred after a median of 10 days(range 8-23),and platelet engraftment occurred after a median of 11 days(range 8-28).Eight patients achieved long-term stable engraftment:three patients had graft failure,and two of them underwent secondary transplantation(1 case achieved long-term stable engraftment,but graft failure occurred again after hematopoietic reconstruction in another case).The median follow-up time was 53(5-135)months.All of the 11 patients survived,and the blood routine of 9 patients was normal for a long time.Conclusion Syngeneic hematopoietic stem cell transplantation has a good long-term survival rate in the treatment of aplastic anemia,and graft failure is still the most significant problem.